IRCT20211108053010N1 IRCT 2022-05-28 Mazandaran University of Medical Sciences Comparison of the effect of intravenous magnesium sulfate and labetalol on intraoperative bleeding and postoperative edema and ecchymosis in rhinoplasty Comparison of the effect of intravenous magnesium sulfate and labetalol on intraoperative bleeding and postoperative edema and ecchymosis in rhinoplasty 2022-05-21 anticipated 60 Complete https://irct.ir/trial/63583 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The samples are randomly divided into two groups using PASS11 software.  Random allocation was performed by Efron method with one thousand repetitions and due to this method, an equal number of samples in each block are placed in two groups of magnesium sulfate and labetalol.  In randomization, equal chances are provided for all samples to be in one of the two groups.  The researcher does not interfere in determining the group for the samples, Blinding description: Blindness is such that only the anesthesiologist is aware of the type of drug being used and all patients, researchers and surgeons are unaware of the patient's reception. 3 Condition 1: Bleeding during rhinoplasty. Condition 2: Edema and ecchymosis after rhinoplasty. Intervention 1: Intervention group: In the sulfate group, 30 to 50 mg / kg intravenous magnesium sulfate is given before induction of anesthesia, and 10 to 20 mg / kg intravenous magnesium sulfate is infused during surgery. Magnesium sulfate is prepared from Shahid Ghazi Pharmaceutical Company, Tabriz, Iran. Intervention 2: Intervention group: In the labetalol group, the infusion of labetalol is 1 mg / min intraoperatively (limit less than 300 mg). Labetalol is produced by Restagen Daru Pharmaceutical Company, Tehran, Iran. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.